MMP9 and glioblastoma: The majority of IDH-1 wild-type glioblastomas (57.5%, 23/40) exhibited MMP-9 immunoexpression, in contrast to IDH1 mutant glioblastomas, where MMP-9 immunoexpression was significantly lower (1/4).